This article is more than 5 years old. Information may no longer be current.
Decreased bleeding, transfusion rate seen with use of tranexamic acid and aspirin during TJA
Click Here to Manage Email Alerts
Among 2,835 patients who underwent total joint arthroplasty and received aspirin for venous thromboembolism prophylaxis, investigators of this retrospective study found use of tranexamic acid led to decreased bleeding and transfusion rates without an increased incidence of subsequent venous thromboembolism.
Researchers evaluated the incidence of symptomatic deep vein thrombosis and pulmonary embolism among patients who underwent primary or revision total joint arthroplasty (TJA) and received aspirin for venous thromboembolism. Overall, 1,678 patients received tranexamic acid and 1,157 did not.
Results showed the tranexamic acid group had no incidences of deep vein thrombosis and three patients who did not receive tranexamic acid experienced deep vein thrombosis, while both groups had the same number of pulmonary emboli. Researchers noted a significantly lower mean calculated blood loss among patients who received tranexamic acid during primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) vs. patients who did not receive tranexamic acid. Compared with patients who did not receive tranexamic acid, the transfusion rate was lower among patients who underwent primary TJA and who received tranexamic acid, with more prominent differences identified among patients who had revision surgery. – by Casey Tingle
Disclosures: Heller reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts